Isomorphic Labs in Talks to Raise $5 Billion at a $50 Billion Valuation: What Founders Can Learn

Isomorphic Labs, the DeepMind spinout led by Demis Hassabis, is in talks to raise about $5 billion at a $50 billion valuation, according to Bloomberg as reported by Tech Funding News on November 5, 2026. The financing is not final and the terms may change, so this is a report and not an announced round.

The Reported Numbers

The figure sits at the upper end of earlier reports of a valuation of $40 billion or more. Isomorphic did not disclose a valuation for its May round, so there is no public benchmark to compare against. In March 2025 the company raised $600 million in its first external round, led by Thrive Capital, GV and Alphabet. A $2.1 billion Series B closed on May 12, 2026, led by Thrive with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. If the new round closes, total external funding would be about $7.7 billion in under two years. By our arithmetic, $5 billion at $50 billion is about 10 percent of the company if the valuation includes the new money, and about 9 percent if it does not.

What the Company Does

Isomorphic spun out of Google DeepMind in 2021 to build on AlphaFold, the protein structure prediction system. Its Isomorphic Drug Design Engine, known as IsoDDE, is a set of AI models that predict molecular structures and interactions so candidates can be designed and refined before lab work. It has in-house programmes in oncology and immune disorders, and partnerships with Eli Lilly and Novartis, signed in January 2024 for up to $1.7 billion and $1.2 billion in milestone payments, and with Johnson & Johnson, which joined in January 2026 on undisclosed terms. Milestone payments depend on development progress and are not guaranteed. As of May, the company had more than 350 staff across London, Cambridge in Massachusetts and Lausanne.

The Clinical Trial Question

Demis Hassabis expects the company's first clinical trials to begin by the end of December, according to the report. That is the milestone investors are watching. A trial start would not show a drug works, but it would show that the company can move a candidate into human testing. Tech Funding News notes that an earlier timeline slipped in 2025, so another delay would leave the valuation resting on partnerships and technical claims that have not been tested in patients.

How the Valuation Compares

The gap to peers is large. Chai Discovery raised $400 million at $3.8 billion in July, so Isomorphic's reported valuation is about 13 times higher. Basecamp Research raised $140 million at $800 million in September, making Isomorphic more than 60 times larger by valuation. Thrive led both of Isomorphic's rounds and also invested in Chai. Grand View Research forecasts the AI drug discovery market at $13.8 billion by 2033, up from $2.3 billion in 2025, which means a $50 billion company would be worth about 3.6 times that projected annual market. Bloomberg also reported competition from OpenAI, which launched a life sciences research model this year.

Lessons for Founders

Valuations in AI-driven science are set by belief in a platform, not by revenue. Founders in deep tech should know which milestone will prove their platform and put dates on it, because investors will hold them to those dates.

Partnership milestone payments are not cash. The Lilly and Novartis figures are potential payments, so founders reporting such deals should separate upfront cash from contingent amounts, as Tech Funding News does here.

A strong lead investor can carry successive rounds. Thrive has led each of Isomorphic's rounds, which gives the company continuity but also concentrates the cap table. Founders should understand how a repeat lead affects dilution and negotiating leverage in later rounds, and should read any term sheet for pro rata and information rights.

Rounds that are only in talks can change. Wait for confirmation before treating a reported valuation as a benchmark in your own raise.

What We Could Not Confirm

We found only the Tech Funding News report citing Bloomberg, and we could not locate a statement from Isomorphic or Thrive. The round size, valuation and investor list are unconfirmed.

Key Takeaways

Isomorphic Labs is reportedly in talks to raise $5 billion at $50 billion, ahead of a first clinical trial that Hassabis expects by the end of December. The valuation is far above peers, and the trial timeline is the main test.

Browse the investor directory to find funds active in biotech and AI drug discovery, and explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai